Jessica Fye
JPMorgan Chase & Co, Research Division
Great. Good afternoon, everyone. My name is Jess Fye, large-cap biotech analyst at JPMorgan, and we’re continuing the 44th Annual JPMorgan Healthcare Conference today with United Therapeutics.
I’m joined up here by the company’s Chair and CEO, Dr. Martine Rothblatt, who’s going to give a presentation on the business, then we’re going to go into some Q&A. If you’re in the room and you want to ask a question, just raise your hand, and then I’ll bring you a microphone. [Operator Instructions] So with that, let me turn it over to Martine.
Martine Rothblatt
Founder, Chairman & CEO
Thank you, Jess. Thanks, Jess, and thanks, everybody at JPMorgan for coming to the presentation. I’m going to show quite a few slides today and say a lot of words. But I think if you leave here with just 2 words, you will understand United Therapeutics completely. And those 2 words are IPF — that’s 1 word, IPF. And the second word is super-prostacyclin, that too is just 1 word, hyphenated, super-prostacyclin. And I think if you just come away with those 2 words, you will understand the amazing potential that United Therapeutics has.
Now what do those 2 words mean? IPF is an acronym for idiopathic pulmonary fibrosis. And this is a fatal condition that robs patients of their ability to breathe. This IPF indication has been known to medicine for many, many decades. And in all that time, there have just been 2 medicines widely approved for that condition. One new medicine just recently approved in a couple of jurisdictions. And
